vs
AST SpaceMobile, Inc.（ASTS）与Ginkgo Bioworks Holdings, Inc.（DNA）财务数据对比。点击上方公司名可切换其他公司
AST SpaceMobile, Inc.的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.6倍（$54.3M vs $33.4M），过去两年AST SpaceMobile, Inc.的营收复合增速更高（173.4% vs -6.2%）
AST SpaceMobile是总部位于美国得克萨斯州米德兰的上市卫星设计与制造企业，目前正搭建SpaceMobile卫星星座，打造可直接对接未改装普通智能手机的天基蜂窝宽带网络，面向全球偏远及通信服务薄弱地区提供4G、5G宽带覆盖服务。
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
ASTS vs DNA — 直观对比
营收规模更大
ASTS
是对方的1.6倍
$33.4M
两年增速更快
ASTS
近两年复合增速
-6.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $54.3M | $33.4M |
| 净利润 | — | — |
| 毛利率 | — | — |
| 营业利润率 | -560.4% | -211.9% |
| 净利率 | — | — |
| 营收同比 | — | -23.8% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | — | $-1.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTSDNA
| Q1 26 | $54.3M | — | ||
| Q4 25 | $54.3M | $33.4M | ||
| Q3 25 | $14.7M | $38.8M | ||
| Q2 25 | — | $49.6M | ||
| Q1 25 | — | $48.3M | ||
| Q4 24 | — | $43.8M | ||
| Q3 24 | — | $89.0M | ||
| Q2 24 | — | $56.2M |
净利润ASTSDNA
| Q1 26 | — | — | ||
| Q4 25 | $-74.0M | — | ||
| Q3 25 | $-122.9M | $-80.8M | ||
| Q2 25 | — | $-60.3M | ||
| Q1 25 | — | $-91.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-56.4M | ||
| Q2 24 | — | $-217.2M |
营业利润率ASTSDNA
| Q1 26 | -560.4% | — | ||
| Q4 25 | -175.0% | -211.9% | ||
| Q3 25 | -1109.0% | -231.8% | ||
| Q2 25 | — | -132.1% | ||
| Q1 25 | — | -184.1% | ||
| Q4 24 | — | -236.3% | ||
| Q3 24 | — | -62.0% | ||
| Q2 24 | — | -396.7% |
净利率ASTSDNA
| Q1 26 | — | — | ||
| Q4 25 | -136.2% | — | ||
| Q3 25 | -833.7% | -207.9% | ||
| Q2 25 | — | -121.6% | ||
| Q1 25 | — | -188.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -63.3% | ||
| Q2 24 | — | -386.4% |
每股收益（稀释后）ASTSDNA
| Q1 26 | — | — | ||
| Q4 25 | — | $-1.41 | ||
| Q3 25 | — | $-1.45 | ||
| Q2 25 | — | $-1.10 | ||
| Q1 25 | — | $-1.68 | ||
| Q4 24 | — | $-1.91 | ||
| Q3 24 | — | $-1.08 | ||
| Q2 24 | — | $-4.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.3B | $422.6M |
| 总债务越低越好 | $12.0M | — |
| 股东权益账面价值 | $2.4B | $508.6M |
| 总资产 | $5.0B | $1.1B |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
现金及短期投资ASTSDNA
| Q1 26 | $2.3B | — | ||
| Q4 25 | $4.3B | $422.6M | ||
| Q3 25 | $2.4B | $495.5M | ||
| Q2 25 | — | $559.4M | ||
| Q1 25 | — | $325.3M | ||
| Q4 24 | — | $561.6M | ||
| Q3 24 | — | $616.2M | ||
| Q2 24 | — | $730.4M |
总债务ASTSDNA
| Q1 26 | $12.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ASTSDNA
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.4B | $508.6M | ||
| Q3 25 | $1.6B | $559.8M | ||
| Q2 25 | — | $613.0M | ||
| Q1 25 | — | $647.4M | ||
| Q4 24 | — | $716.1M | ||
| Q3 24 | — | $797.9M | ||
| Q2 24 | — | $833.1M |
总资产ASTSDNA
| Q1 26 | $5.0B | — | ||
| Q4 25 | $5.0B | $1.1B | ||
| Q3 25 | $2.6B | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B |
负债/权益比ASTSDNA
| Q1 26 | 0.01× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-47.7M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.7M |
| 自由现金流率自由现金流/营收 | — | -142.8% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASTSDNA
| Q1 26 | — | — | ||
| Q4 25 | $65.0M | $-47.7M | ||
| Q3 25 | $-64.5M | $-31.6M | ||
| Q2 25 | — | $-40.3M | ||
| Q1 25 | — | $-51.5M | ||
| Q4 24 | — | $-42.4M | ||
| Q3 24 | — | $-103.5M | ||
| Q2 24 | — | $-84.4M |
自由现金流ASTSDNA
| Q1 26 | — | — | ||
| Q4 25 | $-330.7M | $-47.7M | ||
| Q3 25 | $-302.9M | — | ||
| Q2 25 | — | $-40.3M | ||
| Q1 25 | — | $-59.1M | ||
| Q4 24 | — | $-56.1M | ||
| Q3 24 | — | $-118.6M | ||
| Q2 24 | — | $-111.4M |
自由现金流率ASTSDNA
| Q1 26 | — | — | ||
| Q4 25 | -609.0% | -142.8% | ||
| Q3 25 | -2055.0% | — | ||
| Q2 25 | — | -81.2% | ||
| Q1 25 | — | -122.4% | ||
| Q4 24 | — | -128.0% | ||
| Q3 24 | — | -133.2% | ||
| Q2 24 | — | -198.2% |
资本支出强度ASTSDNA
| Q1 26 | — | — | ||
| Q4 25 | 728.7% | 0.0% | ||
| Q3 25 | 1617.6% | 0.0% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 15.8% | ||
| Q4 24 | — | 31.3% | ||
| Q3 24 | — | 16.9% | ||
| Q2 24 | — | 48.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASTS
暂无分部数据
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
